Neoplasms, Glandular and Epithelial
Welcome,         Profile    Billing    Logout  
 288 Companies   340 Products   340 Products   208 Mechanisms of Action   11 Trials   3342 News 


12345678910111213...6869»
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial completion date, Trial primary completion date:  ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov) -  Jul 7, 2023   
    P=N/A,  N=440, Active, not recruiting, 
    Suspended --> Terminated; There was recruted subject Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Enrollment change:  Study of MOC31-PE in Antigen Positive Carcinomas (clinicaltrials.gov) -  May 8, 2023   
    P1,  N=20, Completed, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 N=30 --> 20
  • ||||||||||  Erivedge (vismodegib) / Roche
    Trial completion, Combination therapy, Metastases:  Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) -  Apr 26, 2019   
    P2,  N=98, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2019 --> Jul 2018 Active, not recruiting --> Completed
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Phase classification, Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Apr 20, 2019   
    P1/2,  N=51, Completed, 
    Active, not recruiting --> Completed Phase classification: P2 --> P1/2
  • ||||||||||  Biomarker, Enrollment change, Trial termination, IO biomarker:  Identification of Key Blood Molecular Markers for Immunotherapy (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=191, Terminated, 
    Phase classification: P2 --> P1/2 N=300 --> 191 | Suspended --> Terminated; Improving assay methods
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Community-Driven Cervical Cancer Prevention in Western Kenya (clinicaltrials.gov) -  Apr 19, 2019   
    P=N/A,  N=7200, Completed, 
    N=18 --> 34 | Trial completion date: Dec 2018 --> May 2019 Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence (clinicaltrials.gov) -  Apr 19, 2019   
    P2/3,  N=1108, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial withdrawal, Metastases:  HIPPO-S: HS-PCI in Locally Advanced Adenocarcinoma of the Lung (clinicaltrials.gov) -  Apr 17, 2019   
    P3,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=438 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Trial completion date, Trial termination, Trial primary completion date, Metastases:  Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol (clinicaltrials.gov) -  Mar 15, 2019   
    P2,  N=17, Terminated, 
    N=438 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Dec 2022 --> Feb 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Feb 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (clinicaltrials.gov) -  Mar 7, 2019   
    P2,  N=2000, Completed, 
    Recruiting --> Completed | Trial completion date: Apr 2019 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019 Recruiting --> Completed | N=1500 --> 2000 | Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019
  • ||||||||||  NanO2 (perflenapent) / NuvOx Pharma
    Trial completion, Enrollment change, Trial completion date:  The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma (clinicaltrials.gov) -  Feb 28, 2019   
    P1b,  N=11, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Apr 2017 Active, not recruiting --> Completed | N=25 --> 11 | Trial completion date: Dec 2017 --> Apr 2018
  • ||||||||||  Lipotecan (TLC388) / Taiwan Liposome Company
    Trial termination, Metastases:  Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 26, 2019   
    P2,  N=29, Terminated, 
    Active, not recruiting --> Completed | N=25 --> 11 | Trial completion date: Dec 2017 --> Apr 2018 Completed --> Terminated; Current study design couldn't support futher development on this indication
  • ||||||||||  oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  IXOGoo1: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. (clinicaltrials.gov) -  Feb 25, 2019   
    P2,  N=47, Completed, 
    Completed --> Terminated; Current study design couldn't support futher development on this indication Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> May 2018 | Trial primary completion date: Jan 2017 --> May 2018
  • ||||||||||  Biomarker, Enrollment change, Trial termination:  Protein Biomarker in Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 16, 2019   
    P=N/A,  N=211, Terminated, 
    Active, not recruiting --> Completed N=1050 --> 211 | Suspended --> Terminated; Loss of funding due to difficulty with recruitment and participant retention.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  EC-Cap-SC: Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (clinicaltrials.gov) -  Feb 12, 2019   
    P=N/A,  N=561, Completed, 
    N=1050 --> 211 | Suspended --> Terminated; Loss of funding due to difficulty with recruitment and participant retention. Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Feb 2019
  • ||||||||||  Javlor (vinflunine) / Pierre Fabre
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer (clinicaltrials.gov) -  Feb 4, 2019   
    P3,  N=459, Completed, 
    Trial completion date: Mar 2018 --> Feb 2019 | Trial primary completion date: Mar 2018 --> Feb 2019 Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2018 | Trial primary completion date: Jun 2018 --> Oct 2017
  • ||||||||||  sorafenib / Generic mfg.
    Trial completion:  Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. (clinicaltrials.gov) -  Jan 19, 2019   
    P2,  N=44, Completed, 
    Completed --> Terminated; The applicant decided to close the study Active, not recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial completion, Trial completion date, Metastases:  Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (clinicaltrials.gov) -  Jan 18, 2019   
    P3,  N=370, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: May 2019 --> Nov 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  Community-Driven Cervical Cancer Prevention in Western Kenya (clinicaltrials.gov) -  Jan 16, 2019   
    P=N/A,  N=7200, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2019 --> Nov 2018 Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Feb 2019 | Trial primary completion date: Dec 2018 --> Oct 2016